Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


"Roche May Be Right" In Not Taking To Generic Drugs - IMS Health; "Innovation Surge" From 2016 Will Help Big Pharma

This article was originally published in PharmAsia News

Executive Summary

MUMBAI - Global pharmaceutical companies - traditionally originators of blockbuster drugs - may not be expected to become part of a "long list of generic players" even by 2020, according to leading industry data and consulting firm IMS Health. However, experts believe MNCs will pursue specific areas where their skill sets can offer competitive advantages

Related Content

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts